CN104981697B - 促染色质转录复合物(fact)在癌症中的用途 - Google Patents

促染色质转录复合物(fact)在癌症中的用途 Download PDF

Info

Publication number
CN104981697B
CN104981697B CN201480008187.8A CN201480008187A CN104981697B CN 104981697 B CN104981697 B CN 104981697B CN 201480008187 A CN201480008187 A CN 201480008187A CN 104981697 B CN104981697 B CN 104981697B
Authority
CN
China
Prior art keywords
fact
tumor
application
cancer
ssrp1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201480008187.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN104981697A (zh
Inventor
卡特琳娜·古罗娃
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
British Ltd By Share Ltd
Original Assignee
Incuron LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incuron LLC filed Critical Incuron LLC
Publication of CN104981697A publication Critical patent/CN104981697A/zh
Application granted granted Critical
Publication of CN104981697B publication Critical patent/CN104981697B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN201480008187.8A 2013-02-11 2014-02-11 促染色质转录复合物(fact)在癌症中的用途 Expired - Fee Related CN104981697B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361763266P 2013-02-11 2013-02-11
US61/763,266 2013-02-11
US201361883802P 2013-09-27 2013-09-27
US61/883,802 2013-09-27
PCT/US2014/015854 WO2014124454A1 (en) 2013-02-11 2014-02-11 Use of facilitates chromatin transcription complex (fact) in cancer

Publications (2)

Publication Number Publication Date
CN104981697A CN104981697A (zh) 2015-10-14
CN104981697B true CN104981697B (zh) 2017-08-04

Family

ID=51300203

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480008187.8A Expired - Fee Related CN104981697B (zh) 2013-02-11 2014-02-11 促染色质转录复合物(fact)在癌症中的用途

Country Status (6)

Country Link
US (1) US10386370B2 (cg-RX-API-DMAC10.html)
EP (1) EP2954331B1 (cg-RX-API-DMAC10.html)
JP (1) JP6576249B2 (cg-RX-API-DMAC10.html)
CN (1) CN104981697B (cg-RX-API-DMAC10.html)
EA (1) EA036615B1 (cg-RX-API-DMAC10.html)
WO (1) WO2014124454A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108333366B (zh) * 2018-01-26 2020-06-12 南通大学附属医院 一种实验性监测肝细胞恶性转化过程大鼠模型的建立方法
CN109136376B (zh) * 2018-05-21 2021-09-21 中国医科大学附属第四医院 一种膀胱癌相关环状RNA的应用和siRNA及其用途
CN113721020B (zh) * 2021-09-14 2022-06-24 大连医科大学附属第二医院 Ctsf在非小细胞肺癌诊断中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2715680A1 (de) 1977-04-07 1978-10-12 Henkel Kgaa Haarfaerbemittel
US7081340B2 (en) 2002-03-13 2006-07-25 Genomic Health, Inc. Gene expression profiling in biopsied tumor tissues
AU2003272175A1 (en) 2002-10-21 2004-05-04 Aprea Ab Reactivation of wild type p53 in human tumour cells by a low molecular weight compound
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
CA3061769C (en) 2003-06-24 2021-10-26 Genomic Health, Inc. Methods of predicting the likelihood of long-term survival of a human patient with node-negative, estrogen receptor (er) positive, invasive ductal breast cancer without the recurrence of breast cancer
ES2905579T3 (es) 2003-07-10 2022-04-11 Genomic Health Inc Algoritmo del perfil de expresión y prueba para el pronóstico de la recaída del cáncer de mama
US7169802B2 (en) 2003-12-23 2007-01-30 Cephalon, Inc. Fused pyrrolocarbazoles
US20100047783A1 (en) 2006-06-20 2010-02-25 El-Diery Wafik S Small molecule modulators of p53 family signaling
WO2009055823A2 (en) 2007-10-26 2009-04-30 Progen Pharmaceuticals Limited Method to predict responsiveness of breast cancer to polyaminetype chemotherapy
AU2009246009A1 (en) 2008-05-14 2009-11-19 University Health Network Prognostic and predictive gene signature for non-small cell lung cancer and adjuvant chemotherapy
GEP20156300B (en) 2008-05-20 2015-06-25 Incuron Llc Inducing cell death by inhibiting adaptive heat shock response
US20100081666A1 (en) 2008-07-14 2010-04-01 Wyeth Src activation for determining cancer prognosis and as a target for cancer therapy
UA107652C2 (en) 2008-10-06 2015-02-10 Incuron Llc Carbazole compounds and therapeutic uses of the compounds
US20100331210A1 (en) 2009-05-29 2010-12-30 Precision Therapeutics, Inc. Methods and systems for evaluating the sensitivity or resistance of tumor specimens to chemotherapeutic agents
EP2830616A1 (en) 2012-03-27 2015-02-04 Incuron LLC Curaxins for use in treating breast cancer and method for identifying patients likely to respond
US20140066465A1 (en) 2012-09-04 2014-03-06 The Cleveland Clinic Foundation CANCER TREATMENT USING TYROSINE KINASE AND NF-kB INHIBITORS

Also Published As

Publication number Publication date
EP2954331A1 (en) 2015-12-16
CN104981697A (zh) 2015-10-14
EP2954331B1 (en) 2018-03-28
WO2014124454A1 (en) 2014-08-14
US20160033515A1 (en) 2016-02-04
US10386370B2 (en) 2019-08-20
HK1218953A1 (en) 2017-03-17
EA201591304A1 (ru) 2016-01-29
EA036615B1 (ru) 2020-11-30
JP2016514248A (ja) 2016-05-19
JP6576249B2 (ja) 2019-09-18
EP2954331A4 (en) 2016-08-31

Similar Documents

Publication Publication Date Title
JP6900314B2 (ja) 膀胱癌の治療、診断、及び予後判定方法
Go et al. High MET gene copy number leads to shorter survival in patients with non-small cell lung cancer
JP5971769B2 (ja) アントラサイクリン療法を用いて乳癌を処置する方法
EP3458610B1 (en) Therapeutic treatment of breast cancer based on c-maf status
KR20170094165A (ko) 화학요법-내성 암을 치료 및 진단하는 조성물 및 방법
WO2013052480A1 (en) Marker-based prognostic risk score in colon cancer
JP2015530072A (ja) ゲムシタビン療法による乳癌の治療方法
WO2007035744A1 (en) Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
CN102132160A (zh) 与转移有关的信号和决定子以及它们的使用方法及用途
JP7236164B2 (ja) 治療法に対する応答を予測する薬剤及び方法
CN115997123A (zh) 用于预测实体癌患者在术前辅助治疗后复发和/或死亡风险的方法
Jung et al. Update on C-cell neuroendocrine neoplasm: prognostic and predictive histopathologic and molecular features of medullary thyroid carcinoma
WO2011106709A2 (en) Epithelial biomarkers for cancer prognosis
JP7741831B2 (ja) 術前補助療法及び根治手術後の固形がんを患っている患者の再発及び／又は死亡のリスクを予測するための方法
Massihnia et al. A headlight on liquid biopsies: a challenging tool for breast cancer management
US10386370B2 (en) Use of facilitates chromatin transcription complex (FACT) in cancer
WO2021170777A1 (en) Methods for diagnosing, prognosing and managing treatment of breast cancer
JP2018500895A (ja) タキサン療法による乳癌治療
US20150309031A2 (en) Compositions and methods for prognosis and treatment of cancer
US8609354B2 (en) Method for selecting patients for treatment with an EGFR inhibitor
JP2013521487A (ja) Ｅｇｆｒ阻害剤を用いる処置のための患者を選択する方法
JP2023535811A (ja) ＨＥＲ２陽性乳癌を患う患者の予後診断を行うｉｎ ｖｉｔｒｏ方法
HK1218953B (en) Use of facilitates chromatin transcription complex (fact) in cancer
US11851709B2 (en) HER2 as a predictor of response to dual HER2 blockade in the absence of cytotoxic therapy
JP6478417B2 (ja) 大腸癌患者の生存を予測及び改善するための方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20180524

Address after: American New York

Patentee after: British Limited by Share Ltd

Address before: American New York

Patentee before: Incuron LLC

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20170804

Termination date: 20210211